CSL-360
As of the edition of 20 October 2026, CSL-360 is a drug: went quiet in 2009; acts on IL3RA.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2009
- Kind
- Unknown
- Registered trials
- 1, 0 stopped early
- Disease areas
- Blood and lymph; Cancer
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of CSL-360.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| IL3RA | Interleukin-3 receptor subunit alpha | P26951 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| All trials | 1 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Sanofi | Lead sponsor of trials | 2006 to now |